Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €75.51 EUR
Change Today -0.69 / -0.90%
Volume 7.2K
BIO On Other Exchanges
As of 3:35 PM 05/26/15 All times are local (Market data is delayed by at least 15 minutes).

biotest ag (BIO) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/16/15 - €105.90
52 Week Low
08/12/14 - €68.50
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BIOTEST AG (BIO)

Related News

No related news articles were found.

biotest ag (BIO) Related Businessweek News

No Related Businessweek News Found

biotest ag (BIO) Details

Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological medicinal products worldwide. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in haematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin for the treatment of haemophilia A acute therapy and prophylaxis; Haemonine for haemophilia B acute therapy and prophylaxis; Bivigam for the treatment of primary immune deficiency; Cytotect for cytomegalovirus (CMV) infections; Fovepta for hepatitis B prophylaxis in newborns; Hepatect CP for the treatment of hepatitis B re-infection prophylaxis; Nabi-HB for post exposure prophylaxis; Intratect for primary immune and secondary antibody deficiency syndromes, as well as for autoimmune diseases; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. The company also provides Albiomin for the treatment of blood volume depletion; Biseko to treat volume and serum protein depletion; Cofact for the treatment of clotting factors deficiency; and Pentaglobin to treat bacterial infections. In addition, its products under development include Indatuximab Ravtansine (BT-062) for multiple myeloma and solid tumors; BT-063 for the treatment of systemic lupus erythematosus; BT-094 (Cytotect 70) to treat CMV infections; Civacir for the treatment of hepatitis C infection; Tregalizumab (BT-061) for rheumatoid arthritis and psoriasis; Fibrinogen to treat fibrinogen deficiency; and IgM concentrate for the treatment of bacterial infections. It has a collaboration agreement with AbbVie for the development of monoclonal antibody BT-061. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. Biotest Aktiengesellschaft was founded in 1946 and is headquartered in Dreieich, Germany.

2,188 Employees
Last Reported Date: 05/7/15
Founded in 1946

biotest ag (BIO) Top Compensated Officers

Chairman of the Board of Management and Chief...
Total Annual Compensation: €70.0K
Chief Financial Officer, Head of Finances & C...
Total Annual Compensation: €423.0K
Chief Operating Officer and Member of Board o...
Total Annual Compensation: €370.0K
Compensation as of Fiscal Year 2014.

biotest ag (BIO) Key Developments

Biotest AG Approves Dividend on Ordinary Share and Preference Share

At the annual general meeting held on 7 May 2015, shareholders of Biotest AG approved the payment of an increased dividend. With 77.54% of the ordinary share capital represented at the meeting, a payment of EUR 0.60 per ordinary share and EUR 0.66 per preference share was resolved with a high degree of approval. The amount of dividends paid increased by 5%. The overall dividend payment will amount to EUR 8.3 million.

Biotest AG Reports Group Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for the Year 2015

Biotest AG reported group earnings results for the first quarter ended March 31, 2015. The Biotest Group again succeeded to increase revenues in the first three months of 2015. The Group generated revenue of EUR 142.5 million in the period from January to March 2015. This represents an increase of 16.6 % compared to EUR 122.2 million reported in the same period in the previous year. Earnings before taxes (EBT) of EUR 4.2 million for the Biotest Group compared to EUR 7.8 million in the same period in the previous year. Earnings after taxes (EAT) also decreased from EUR 5.0 million to EUR 1.5 million. Earnings per share were EUR 0.11 compared to EUR 0.38 for the first three months of 2014. Operating income (EBIT) decreased from EUR 10.7 million to EUR 0.1 million due to the increased research and development costs, costs incurred for the capacity expansion already underway, unabsorbed costs at the US subsidiary, Biotest Pharmaceuticals Corporation, as well as sustained price pressure in individual product areas and regions. For the year 2015, the Board of Management expects that the Biotest Group will continue to perform positively and is aiming for EBIT in the range of some EUR 50 million.

Biotest AG - Special Call

To discuss topline results from the TREAT 2b study [T cell REgulating Arthritis Trial 2b]


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIO:GR €75.51 EUR -0.69

BIO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BIO.
View Industry Companies

Industry Analysis


Industry Average

Valuation BIO Industry Range
Price/Earnings 65.2x
Price/Sales 1.6x
Price/Book 2.0x
Price/Cash Flow 32.9x
TEV/Sales 0.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOTEST AG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at